President/COO Neil Klompas to leave Zymeworks June 30; CEO Galbraith becomes President

Zymeworks Inc.

Departure of President and COO Neil Klompas effective June 30, 2023; consulting agreement through June 30, 2025.
Separation includes $1M lump sum (24 months salary), continued benefits for 24 months, and stock vesting continuation.
CEO Kenneth Galbraith appointed as President in addition to CEO and Chair roles, effective June 30.
Galbraith has over 35 years of biotech executive experience; his compensation terms remain unchanged.
Klompas had been with Zymeworks since 2007, serving as CFO, COO, and President.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Neil Klompas

President and Chief Operating Officer

ZYME · Zymeworks Inc.

Effective: 2023-06-30
Successor: Kenneth Galbraith
Filed: May 18, 2023, 7:59 PM ET

On May 17, 2023, Zymeworks Inc. (the “Company”) and Mr. Neil Klompas, the Company’s President and Chief Operating Officer, mutually agreed to terms pursuant to which Mr. Klompas will step down as the Company’s President and Chief Operating Officer and separate from employment effective as of June 30, 2023

Appointed

Kenneth Galbraith

President

ZYME · Zymeworks Inc.

Effective: 2023-06-30
Filed: May 18, 2023, 7:59 PM ET

the board of directors of the Company (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chief Executive Officer and Chair of the Board, as President of the Company to succeed Mr. Klompas in the role of President of the Company, effective as of the Separation Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Klompas departed as President and Chief Operating Officer at Zymeworks Inc..

Action: step down
Role: President and Chief Operating Officer

Exact text from the filing

On May 17, 2023, Zymeworks Inc. (the “Company”) and Mr. Neil Klompas, the Company’s President and Chief Operating Officer, mutually agreed to terms pursuant to which Mr. Klompas will step down as the Company’s President and Chief Operating Officer and separate from employment effective as of June 30, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Galbraith was appointed as President at Zymeworks Inc..

Action: appointed
Role: President

Exact text from the filing

the board of directors of the Company (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chief Executive Officer and Chair of the Board, as President of the Company to succeed Mr. Klompas in the role of President of the Company, effective as of the Separation Effective Date.

View on SEC.gov

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-147667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.